Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Increased expression of CD69 on T cells as an early immune marker for human cytomegalovirus reactivation in chronic lymphocytic leukemia patients.

Petersen CC, Nederby L, Roug AS, Skovbo A, Peterslund NA, Hokland P, Nielsen B, Hokland M.

Viral Immunol. 2011 Apr;24(2):165-9. doi: 10.1089/vim.2010.0087.

PMID:
21449727
2.

Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.

Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G.

Haematologica. 2004 Oct;89(10):1248-52.

4.

Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation.

Wikell H, Ponandai-Srinivasan S, Mattsson J, Gertow J, Uhlin M.

Transpl Infect Dis. 2014 Apr;16(2):203-12. doi: 10.1111/tid.12182. Epub 2014 Jan 24.

PMID:
24456214
5.

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.

Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, Kimby E, Osterborg A, Mellstedt H.

Leukemia. 2004 Mar;18(3):484-90.

PMID:
14749699
6.

Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.

O'Brien SM, Keating MJ, Mocarski ES.

Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30. Review.

PMID:
17026823
7.

HCMV infection of PDCs deviates the NK cell response into cytokine-producing cells unable to perform cytotoxicity.

Cederarv M, Söderberg-Nauclér C, Odeberg J.

Immunobiology. 2009;214(5):331-41. doi: 10.1016/j.imbio.2008.10.009. Epub 2009 Jan 18.

PMID:
19152985
8.

The CD94/NKG2C-expressing NK cell subset is augmented in chronic lymphocytic leukemia patients with positive human cytomegalovirus serostatus.

Petersen L, Roug AS, Skovbo A, Thysen AH, Eskelund CW, Hokland ME.

Viral Immunol. 2009 Oct;22(5):333-7. doi: 10.1089/vim.2009.0032.

PMID:
19811091
9.

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.

O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M.

Blood. 2008 Feb 15;111(4):1816-9. Epub 2007 Nov 26.

10.

Human cytomegalovirus particles directly suppress CD4 T-lymphocyte activation and proliferation.

Fornara O, Odeberg J, Khan Z, Stragliotto G, Peredo I, Butler L, Söderberg-Nauclér C.

Immunobiology. 2013 Aug;218(8):1034-40. doi: 10.1016/j.imbio.2013.01.002. Epub 2013 Jan 16.

PMID:
23434301
11.

Elevated granzyme M-expressing lymphocytes during cytomegalovirus latency and reactivation after allogeneic stem cell transplantation.

Bovenschen N, Spijkers SN, Wensink AC, Schellens IM, van Domselaar R, van Baarle D.

Clin Immunol. 2014 Jan;150(1):1-11. doi: 10.1016/j.clim.2013.11.005. Epub 2013 Nov 18.

PMID:
24316590
12.

Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.

Mackus WJ, Frakking FN, Grummels A, Gamadia LE, De Bree GJ, Hamann D, Van Lier RA, Van Oers MH.

Blood. 2003 Aug 1;102(3):1057-63. Epub 2003 Apr 10.

13.

Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment.

Engstrand M, Lidehall AK, Totterman TH, Herrman B, Eriksson BM, Korsgren O.

Clin Exp Immunol. 2003 Apr;132(1):96-104.

14.

Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation.

Ludwig B, Kraus FB, Kipp M, Preiser W, Schwerdtfeger R, Doerr HW, Buxbaum S.

J Clin Virol. 2006 Feb;35(2):160-6. Epub 2005 Aug 19.

PMID:
16112610
15.

Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis.

Romo N, Fitó M, Gumá M, Sala J, García C, Ramos R, Muntasell A, Masiá R, Bruguera J, Subirana I, Vila J, de Groot E, Elosua R, Marrugat J, López-Botet M.

Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2314-21. doi: 10.1161/ATVBAHA.111.233288. Epub 2011 Aug 4.

PMID:
21817101
16.

Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses.

Riou R, Bressollette-Bodin C, Boutoille D, Gagne K, Rodallec A, Lefebvre M, Raffi F, Senitzer D, Imbert-Marcille BM, Retière C.

J Virol. 2017 Feb 14;91(5). pii: e02245-16. doi: 10.1128/JVI.02245-16. Print 2017 Mar 1.

17.
18.

The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir.

Isidori A, Visani G.

Leuk Lymphoma. 2009 Feb;50(2):294-6. doi: 10.1080/10428190802627580. No abstract available.

PMID:
19197728
19.

Detection of human cytomegalovirus-specific T lymphocytes in human blood: comparison of two methods.

Schermann CM, Fischer G, Witt V, Kurz M, Potschger U, Fritsch G.

Cytotherapy. 2008;10(8):834-41. doi: 10.1080/14653240802474315.

PMID:
19016371
20.

Monoclonal antibodies in the treatment of chronic lymphoid leukemias.

Robak T.

Leuk Lymphoma. 2004 Feb;45(2):205-19. Review.

PMID:
15101704

Supplemental Content

Support Center